News und Analysen
![Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine
![Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer
Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with
![Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to
![Pfizer Declares Third-Quarter 2020 Dividend](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Declares Third-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of
![Bayer: Darum bricht die Aktie heute so stark ein!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Bayer: Darum bricht die Aktie heute so stark ein!
Gestern gab es gleich zwei positive Nachrichten des Leverkusener Bayer-Konzerns (WKN: BAY001), die sich jedoch erst heute auf den Aktienkurs auswirken konnten. Denn leider kamen die News erst nach
![Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private
![Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers
Waters Corporation (NYSE:WAT) announced today a new fragmentation technique and an imaging option for its high-resolution mass spectrometers giving research scientists working across a broad range
![Waters Introduces the New Arc High-Performance Liquid Chromatograph to Help Laboratories Meet Quality and Production Targets](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Waters Introduces the New Arc High-Performance Liquid Chromatograph to Help Laboratories Meet Quality and Production Targets
Waters Corporation (NYSE:WAT) today introduced the Waters™ Arc™ HPLC System, a new high-performance liquid chromatograph (HPLC) for routine testing in the pharmaceutical, food, academic and
![Illumina Accelerator Welcomes First Global Cohort of Genomics Startups](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
![Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines
Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines:
-
Two studies (NCT04382326 and NCT04379713) of the
![Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec
![Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Humana’s 2020 Bold Goal Progress Report Details Improved Mental and Physical Health Among its Population
Humana Inc. (NYSE: HUM) today unveiled its “2020 Bold Goal Progress Report,” which details the company’s progress in its ambitious population health strategy launched in 2015 to improve the health
![Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
Upjohn Inc. (“Newco”), a wholly-owned subsidiary of Pfizer Inc. (“Pfizer”) (NYSE: PFE), Upjohn Finance B.V. (“Finco”), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. (“Mylan”) (Nasdaq
![Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Acquires BlueBee to Accelerate Processing, Analysis and Sharing of Next Generation Sequencing Data at Scale
Illumina, Inc. (NASDAQ: ILMN) is enhancing its capabilities to analyze and interpret the data produced by its sequencing systems with the acquisition of BlueBee, a cloud-based software company that
![Waters Corporation Announces CEO Succession Plan](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Waters Corporation Announces CEO Succession Plan
Waters Corporation (NYSE:WAT) today announced that the Company’s Board of Directors and Christopher O’Connell have mutually agreed that Mr. O’Connell will step down as President, Chief Executive
![Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Illumina Inc. Announces that U.S. Federal Court Issues Preliminary Injunction Against BGI Companies
Illumina, Inc. (NASDAQ: ILMN) today announced that the U.S. District Court for the Northern District of California issued a preliminary injunction order against several BGI companies, including MGI
![Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 28, 2020. The purpose
![Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Humana Announces Monthly Stipend to Reduce Costs for Dental Providers During Pandemic
Today, Humana Inc. (NYSE: HUM) announced new actions it is taking to support participating dental providers – to help them afford the increased costs of doing business during the coronavirus
![AstraZeneca: Kurs-Irrsinn nach Impfstoff-News](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
AstraZeneca: Kurs-Irrsinn nach Impfstoff-News
Papiere des britischen Pharmakonzerns AstraZeneca (WKN: 886455) verteuern sich heute Morgen um zeitweise +30% auf 120 Euro. Börsenlaien lassen sich von einem am Wochenende vermeldeten Impfstoff-Deal
![Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Thursday, June 18, 2020 at 11:30 a.m. EDT. The
![Bayer: Aktie weiterhin ein Schnäppchen!](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Bayer: Aktie weiterhin ein Schnäppchen!
Nachdem es an der Börse wochenlang quasi nur nach oben ging, sahen wir gestern endlich mal wieder einen Korrekturtag. Aufgrund des Sell Offs geriet letztlich auch die Aktie von Bayer (WKN: BAY001)
![Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Quidel Announces Jack Schuler Will Retire From Quidel’s Board of Directors
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler
![FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA™ (pegfilgrastim-apgf), a biosimilar to Neulasta® (pegfilgrastim).1 NYVEPRIA
![Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12